Merrimack is committed to the fight against cancer. We are a science-driven community seeking to understand the complexity of the disease, engineer better solutions and deliver life-saving results for patients.
We believe the key to achieving a deeper understanding of the complex and dynamic biology behind cancer requires a systems-based understanding of the interactions within a cancer cell and its surrounding environment. Our researchers apply systems biology as a tool to discover and develop better medicines.
Merrimack is using its novel antibody-engineering platform to design therapies targeting critical nodes of the complex signaling pathways that drive many cancers. These approaches consist of developing monoclonal, oligoclonal, bispecific and multispecific antibody based therapies targeting multiple different receptors across various types of cancers.
Merrimack leverages its proprietary nanoliposomal technology to design and develop therapeutics intended to deliver greater concentrations of drug to the tumor site while reducing off-target effects. Through this approach, we believe our nanotechnology platform provides us with the potential to significantly improve the impact of a broad range of therapeutics.
Merrimack is currently using insights gained from our systems biology approach to develop diagnostics designed to help physicians identify which regimens will be best suited for each patient we treat.
Merrimack currently has six therapeutic oncology candidates at different stages of clinical development, multiple product candidates in preclinical development, and an active Network Biology-focused discovery effort.
MM-398 in combination with 5-fluorouracil and leucovorin demonstrates a statistically significant advantage in overall survival compared to the control arm, in patients with metastatic pancreatic cancer who have been previously treated with gemcitabine.
Read more about the trial results here.
Professor Peter Sorger of Harvard Medical School discusses the science of systems biology and its potential impact on cancer care.
Merrimack was thrilled to participate in the 2nd Annual Battle of the Biotech Bands charity benefit event. The event raised over $60,000 and was attended by over 700 industry representatives. Merrimack’s BAD IDEA took top honors and awarded over $30,000 to our charity of choice - Dream Day on Cape Cod – a worthy cause serving families that have children with life-threatening illnesses or serious conditions. We thank everyone who made this event possible and look forward to participating again next year!
Baxter gains exclusive commercialization rights for all potential indications of MM-398 outside the United States and Taiwan. Merrimack retains commercialization rights in the United States. Under the terms of the agreement,Merrimack will receive a $100 million upfront payment from Baxter and is eligible to receive up to $870 million for additional milestone and royalty payments.